CTOs on the Move

Kootenai Medical Center

www.kh.org

 
Kootenai Health provides a comprehensive range of medical services to patients in north Idaho, eastern Washington, Montana and the Inland Northwest at several facility locations. The main campus at Kootenai Health is located in Coeur d`Alene, Idaho and includes a 299-bed community-owned hospital. By providing outstanding health care, Kootenai Health repeatedly earns regional and national recognition.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.kh.org
  • 2003 Kootenai Health Way
    Coeur d`Alene, ID USA 83814
  • Phone: 208.625.4000

Executives

Name Title Contact Details

Similar Companies

Hunstman Expandable Polymers Co.

Hunstman Expandable Polymers Co. is a High Point, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gauthier Biomedical

Gauthier Biomedical is a Grafton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edmund Optics

Edmund Optics (EO) has been a leading supplier of precision optics and optical components since 1942, designing and manufacturing a wide array of multi-element optical lenses, lens coatings, imaging systems, and optomechanical equipment. Led by a staff of skilled optical engineers and scientists, EO is application focused and pursues new ways to implement optical technology, enabling advancements in industrial metrology, semiconductor manufacturing, life sciences, and more. EO is a worldwide presence in industrial optics extending well beyond our original manufacturing plant and corporate headquarters in Barrington, New Jersey, USA.

WebOps

WebOps is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.